How to design nutritional intervention trials to slow cognitive decline in apparently healthy populations and apply for efficacy claims: A statement from the international academy on nutrition and aging task force
Open Access
- 16 July 2013
- journal article
- review article
- Published by Elsevier in The Journal of nutrition, health and aging
- Vol. 17 (7) , 619-623
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Antioxidants for Alzheimer DiseaseArchives of Neurology, 2012
- Report of the task force on designing clinical trials in early (predementia) ADNeurology, 2011
- Adherence to nutritional recommendations and subsequent cognitive performance: findings from the prospective Supplementation with Antioxidant Vitamins and Minerals 2 (SU.VI.MAX 2) studyThe American Journal of Clinical Nutrition, 2011
- Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer DiseaseJAMA, 2010
- Effect of 2-y n−3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trialThe American Journal of Clinical Nutrition, 2010
- Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trialNutrition & Metabolism, 2009
- High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer DiseaseJAMA, 2008
- Endpoints for trials in Alzheimer's disease: a European task force consensusThe Lancet Neurology, 2008
- Dietary patterns and risk of dementiaNeurology, 2007
- Amnestic syndrome of the medial temporal type identifies prodromal ADNeurology, 2007